DFDA

MAO-B Inhibitors (e.g., Rasagiline, Selegiline)

Treatment for Parkinson S Disease

Typical Dosage: Rasagiline 0.5-1 mg daily; Selegiline 5 mg BID

Effectiveness
70%
Safety Score
70%
Clinical Trials
70
Participants
15K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Rasagiline 0.5-1 mg daily; Selegiline 5 mg BID
Time to Effect
1-2 weeks
Treatment Duration
Lifetime
Evidence Quality
MODERATE
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$400
Monitoring:$600
Side Effect Mgmt:$100
Total Annual:$1,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$75,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$2,750
Prescription Access Economics
Annual Societal Loss per Patient
$1,020
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$750/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$50/year
Prior auth, claims
Rx Price
$400/year
Potential OTC Price
$200/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
MODERATE
Requires Monitoring
Yes
Needs lab work/checkups
MAO-B Inhibitors (e.g., Rasagiline, Selegiline) Outcomes

for Parkinson S Disease

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+40%
Common Side Effects
Nausea
+12%
Insomnia
+15%
Orthostatic Hypotension
+7%
Headache
+7%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov